Customized for Vaccine Development

Customized for Vaccine Development

Comprehensive Support Across All Stages of Development

Comprehensive Support Across All

Stages of Development

From early discovery to clinical development, our Systems Serology platform provides customizable solutions to support each phase of vaccine development. Whether it’s mechanism of action analysis, functional profiling, or candidate optimization, we offer the insights needed to advance your projects.

STAGES OF VACCINE DEVELOPMENT

*Select a stage to explore its relevant applications.

SCIENTIFIC RESOURCES

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial

September 15, 2025
Authors: Rumyantsev, A., et al. (2025). Safety and immunogenicity of UB-612 heterologous booster: A pivotal Phase 3 study. eClinicalMedicine, The Lancet. Journal: The Lancet

Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies

July 23, 2025
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum 

mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions

May 31, 2025
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.